Gengraf and Indacaterol and glycopyrrolate Inhalation
Determining the interaction of Gengraf and Indacaterol and glycopyrrolate Inhalation and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter. When a single 300 mcg dose of indacaterol inhalation powder was administered in combination with the potent dual CYP450 3A4/P-glycoprotein inhibitor, ketoconazole (200 mcg twice daily for 7 days), indacaterol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.3- and 1.9-fold, respectively. These changes probably reflect the impact of maximal combined inhibition. Similarly, verapamil 80 mg three times a day for 4 days increased indacaterol Cmax by 1.5-fold and AUC by 2-fold, while erythromycin 400 mg four times a day for 7 days increased indacaterol Cmax by 1.2-fold and AUC by 1.4-fold. Ritonavir 300 mg twice daily for 7.5 days had no effect on the Cmax of indacaterol, but increased its AUC by 1.7-fold. Indacaterol oral inhalation powder has been evaluated in clinical trials for up to one year at doses up to 600 mcg. No dosage adjustment is necessary at the 75 mcg dose when used with CYP450 3A4 and P-glycoprotein inhibitors.
- "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: cyclosporine
Brand name: Gengraf, Neoral, Sandimmune, Sandimmune
Synonyms: Gengraf (Capsules, Modified)
Generic Name: glycopyrrolate / indacaterol
Brand name: Utibron Neohaler
Synonyms: Glycopyrrolate and indacaterol (inhalation), Indacaterol and Glycopyrrolate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Gengraf-Indacaterol inhalation
- Gengraf-Indacaterol Maleate
- Gengraf-Indapamide
- Gengraf-Inderal
- Gengraf-Inderal Intravenous
- Gengraf-Inderal LA
- Indacaterol and glycopyrrolate Inhalation-Gengraf (Cyclosporine Capsules, Modified)
- Indacaterol and glycopyrrolate Inhalation-Gengraf (Cyclosporine Oral Solution, Modified)
- Indacaterol and glycopyrrolate Inhalation-Gengraf Capsules
- Indacaterol and glycopyrrolate Inhalation-Gengraf Oral
- Indacaterol and glycopyrrolate Inhalation-Gengraf Oral Solution
- Indacaterol and glycopyrrolate Inhalation-Genicin